DR-022 Comprehensive analysis of mutational signatures in metastatic cancers
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-022 Comprehensive analysis of mutational signatures in metastatic cancers
The DNA in normal – and tumor cells are continuously exposed to internal and external challenges. The objective of this …
DR-021 Targetable yield of whole genome sequencing for glioblastoma
The goal is to investigate the presence of actionable biomarkers in whole genome sequencing (WGS) data of glioblastoma cases and …
DR-019 A comprehensive comparison fo the whole genome sequencing landscape between primary and metastatic cancer tumors
The goal of this study is to systematically compare the mutation landscape and underlying mutagenic mechanisms that are active in …
DR-018 The characterization of homologous recombination deficiency in cancer
Deficiency in DNA repair pathways is a key characteristic in many tumors. The goal of this project is to develop …
DR-017 Identification of non-coding mutations across cancer types
Most studies have focused on mutations in the few percent of the genome that encode proteins. In this study, large …
DR-016 Detectie van structurele varianten in DNA die van invloed zijn op dikkedarmkanker
The researchers will study the involvement of structural variation in the tumor genomes of colorectal cancer patients and investigate their …
DR-015 Voorspellers voor respons op standaard chemotherapie bij colorectaal carcinoom
“In this study genetic factors will be explored that may explain response to standard chemotherapy (FOLFOX/CAPOX/Irinotecan/capecitabine) in coloroctal cancer patients. …
DR-014 Verhoging kwaliteit van zorg door doelgerichtere inzet van medicatie in de oncologie
This project is focused on biomarker discovery for specific targeted treatments in breast cancer patients. Specific focus will be on …
DR-013 Genetic causes of resistance to new androgen receptor signaling inhibitors in circulating tumor DNA of metastasized castration-resistant prostate cancer patients
The research question is focused on the improvement and development of novel treatment approaches in prostate cancer patients that have …
DR-012 Phosophoproteomics for therapy response prediction
The goal of this project is to correlate systematic DNA and protein measurement data from the same patients. This pilot …
DR-011 The landscape of structural variation in metastatic prostate cancer samples
This project aims to create a systematic overview of the mutation landscape of metastatic prostate cancer patients with a special …
DR-010 The prevalence and burden of rare deleterious germline variants
The goal of this project is to identify inherited mutations in genes that result in higher chances to develop cancer …
Als je WGS één keer doet bij een patiënt met gemetastaseerde kanker, weet je meteen alles wat je nodig hebt om een gerichte behandeling te bieden als die – geregistreerd of in onderzoeksetting – beschikbaar is.